Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - toltrazuril - oral suspension - 50 mg/ml - toltrazuril - bovine, ovine, porcine - coccidiostats

United Kingdom - English - VMD (Veterinary Medicines Directorate)

krka d.d., novo mesto - toltrazuril - oral suspension - antiprotozoal anticoccidial - cattle, pigs, sheep

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - toltrazuril 50 mg/ml - oral suspension - 50 mg/ml - toltrazuril 50 mg/ml - toltrazuril - pig; cattle; sheep

United States - English - NLM (National Library of Medicine)

specgx llc - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression – for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis – may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval sho

United States - English - NLM (National Library of Medicine)

thompson medical solutions llc - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression – for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis – may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval sho

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 10 mg - tablet, sugar coated - excipient ingredients: macrogol 8000; povidone; stearic acid; hypromellose; purified talc; glycerol; magnesium stearate; titanium dioxide; maize starch; microcrystalline cellulose; iron oxide red; colloidal anhydrous silica; lactose monohydrate; sucrose; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 25 mg - tablet, sugar coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; sucrose; magnesium stearate; stearic acid; lactose monohydrate; hypromellose; maize starch; glycerol; povidone; iron oxide red; macrogol 8000; carnauba wax; purified talc; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

United States - English - NLM (National Library of Medicine)

geigy pharmaceuticals - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - injection, solution - 25 mg in 2 ml - depression : for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. initial dosage should be low and increases should be gradual and cautiously prescribed. the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the drug. the possibility of cross-sensitivity to other dibenzazepine compounds should be k

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imipramine hydrochloride 10mg - coated tablet - 10 mg - active: imipramine hydrochloride 10mg excipient: colloidal silicon dioxide copovidone glycerol hypromellose 15028 dispersed red lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose povidone purified talc     purified water stearic acid sucrose titanium dioxide - all forms of depression, including endogenous, organic and psychogenic forms, and depression associated with personality disorders or chronic alcoholism.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imipramine hydrochloride 25mg - coated tablet - 25 mg - active: imipramine hydrochloride 25mg excipient: carnauba wax colloidal silicon dioxide copovidone glycerol hypromellose dispersive red isopropyl alcohol lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose povidone purified talc     purified water stearic acid sucrose titanium dioxide   - all forms of depression, including endogenous, organic and psychogenic forms, and depression associated with personality disorders or chronic alcoholism.